Sahaj Innovative Cell Therapy Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-12-2024
- Paid Up Capital ₹ 1.00 M
as on 25-12-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Ebitda
- Net Worth
- Total Assets 1.63%
(FY 2022)
About Sahaj Innovative Cell Therapy
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Priti Jain and Sulochana Bohara serve as directors at the Company.
- CIN/LLPIN
U85190MP2015PTC034259
- Company No.
034259
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sahaj Innovative Cell Therapy?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priti Jain  | Director | 28-May-2015 | Current |
| Sulochana Bohara | Director | 28-May-2015 | Current |
Financial Performance of Sahaj Innovative Cell Therapy.
Sahaj Innovative Cell Therapy Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sahaj Innovative Cell Therapy?
In 2022, Sahaj Innovative Cell Therapy had a public holding of 78.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sahaj Hospitals Private LimitedActive 16 years 4 monthsPriti Jain and Sulochana Bohara are mutual person
- Hope Diagnostic And Fertility Centre Private LimitedActive 22 years 1 month
Priti Jain is a mutual person
- Sahaj Regenerative Cell Therapeutics Private LimitedActive 11 months 9 days
Priti Jain and Sulochana Bohara are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sahaj Innovative Cell Therapy?
Unlock and access historical data on people associated with Sahaj Innovative Cell Therapy, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sahaj Innovative Cell Therapy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sahaj Innovative Cell Therapy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
